Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy

Clin Lung Cancer. 2021 Jan;22(1):e67-e69. doi: 10.1016/j.cllc.2020.08.002. Epub 2020 Aug 26.

Authors

Maria Bonomi¹, Mariangela Maltese², Matteo Brighenti³, Margherita Muri⁴, Rodolfo Passalacqua³

Affiliations

¹ Department of Oncology, ASST Cremona, Cremona, Italy. Electronic address: maria.bonomi@asst-cremona.it.
² Department of Oncology, ASST Cremona, Cremona, Italy; Department of Oncology, Azienda Ospedaliera Papardo, Messina, Italy.
³ Department of Oncology, ASST Cremona, Cremona, Italy.
⁴ Department of Radiology, ASST Cremona, Cremona, Italy.

No abstract available

Keywords: COVID-19; Chemoimmunotherapy; Non–small-cell lung cancer; Tocilizumab.

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
COVID-19 Drug Treatment*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Humans
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use*
Lung Neoplasms / drug therapy*
Male
SARS-CoV-2*

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
tocilizumab